Crossmark

Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer

Crossref DOI link: https://doi.org/10.1007/s00280-019-03855-w

Published Online: 2019-05-07

Published Print: 2019-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Suzuki, Takeshi

Shinozaki, Eiji

Osumi, Hiroki

Nakayama, Izuma

Ota, Yumiko

Ichimura, Takashi

Ogura, Mariko

Wakatsuki, Takeru

Ooki, Akira

Takahari, Daisuke

Suenaga, Mitsukuni

Chin, Keisho

Yamaguchi, Kensei
License Information

Text and Data Mining valid from 2019-05-07
More Information

Article History

Received: 13 February 2019

Accepted: 2 May 2019

First Online: 7 May 2019

Compliance with ethical standards

:

: Honoraria from Takeda, Merck Serono, Taiho, Chugai, Lily, Sanofi, Yakult.